Literature DB >> 20669993

Differentiation and semiquantitative analysis of an isoaspartic acid in human alpha-Crystallin by postsource decay in a curved field reflectron.

Yuzo Yamazaki1, Norihiko Fujii, Yutaka Sadakane, Noriko Fujii.   

Abstract

Alpha-Crystallin, which forms a huge multimeric complex that is essential for maintaining eye lens transparency, is one of the major proteins in the lens. The protein, which exists as isoforms alphaA and alphaB, functions as a molecular chaperone to restore the original conformations of distorted constituent proteins in the lens. This function is important to maintain the transparency of the lens, because there is no protein turnover in the lens. Abnormal aggregation of constituent proteins in the lens has been reported in cataract patients, and deamidation of Asn as well as racemization and isomerization of Asp have been found in the alpha-Crystallin of these patients. While the establishment of a quick and facile analytical method is eagerly anticipated to investigate the relevance of the isomerization to pathological states such as cataracts, differentiating the isomerization states is still not performed routinely. Here, we report the differentiation and semiquantitative analysis of an isoaspartic acid (betaAsp) in human alpha-Crystallin using postsource decay on a MALDI-TOF mass spectrometer incorporating a curved field reflectron. Our reproducible results of analyzing synthetic and tryptic peptides containing betaAsp corroborated results obtained using a previously reported diagnostic ion, y(l-n+1) - 46, for the differentiation of betaAsp. The relative content of betaAsp in the peptide was successfully estimated from a unique ratio, y(l-n):y(l-n+1), corresponding to cleavages at the C- and N-termini, respectively, of the isomeric residues. The betaAsp content was consistent with measurements obtained independently by reversed phase HPLC analysis. Experiments in which neighboring amino acids adjacent to betaAsp/Asp were substituted revealed that the ratio between y(l-n) and y(l-n+1) reflected the isomerization status, while the diagnostic ion was observed only in the peptides that included an arginine residue at their C-terminus. Postsource decay experiments utilizing both the diagnostic ion and the characteristic fragment pattern could be applied to various kinds of peptides containing betaAsp.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20669993     DOI: 10.1021/ac100310x

Source DB:  PubMed          Journal:  Anal Chem        ISSN: 0003-2700            Impact factor:   6.986


  6 in total

1.  Differentiating N-terminal aspartic and isoaspartic acid residues in peptides.

Authors:  Nadezda P Sargaeva; Cheng Lin; Peter B O'Connor
Journal:  Anal Chem       Date:  2011-08-01       Impact factor: 6.986

2.  A rapid, comprehensive liquid chromatography-mass spectrometry (LC-MS)-based survey of the Asp isomers in crystallins from human cataract lenses.

Authors:  Norihiko Fujii; Hiroaki Sakaue; Hiroshi Sasaki; Noriko Fujii
Journal:  J Biol Chem       Date:  2012-09-24       Impact factor: 5.157

3.  Distinguishing Aspartic and Isoaspartic Acids in Peptides by Several Mass Spectrometric Fragmentation Methods.

Authors:  Nick DeGraan-Weber; Jun Zhang; James P Reilly
Journal:  J Am Soc Mass Spectrom       Date:  2016-09-09       Impact factor: 3.109

4.  In-Source Decay Characterization of Isoaspartate and β-Peptides.

Authors:  Xiang Yu; Nadezda P Sargaeva; Christopher J Thompson; Catherine E Costello; Cheng Lin
Journal:  Int J Mass Spectrom       Date:  2015-11-15       Impact factor: 1.986

5.  A DFT calculation on nonenzymatic degradation of isoaspartic residue.

Authors:  Wichien Sang-Aroon; Ratchanee Phatchana; Sarawut Tontapha; Vithaya Ruangpornvisuti
Journal:  J Mol Model       Date:  2021-09-27       Impact factor: 1.810

6.  Isomerization of Asp is essential for assembly of amyloid-like fibrils of αA-crystallin-derived peptide.

Authors:  Kosuke Magami; Naomi Hachiya; Kazuo Morikawa; Noriko Fujii; Takumi Takata
Journal:  PLoS One       Date:  2021-04-15       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.